Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ATRC

AtriCure, Inc.

Healthcare | Medical - Instruments & Supplies

No licensed closing price on file for ATRC. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.21

AtriCure, Inc. (NASDAQ: ATRC) is a medical instruments and supplies company. Figures from SEC EDGAR; updated 2026-10-20 01:49 UTC.

What AtriCure, Inc. does

The company develops surgical products for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain. Atrial fibrillation is an irregular heartbeat affecting millions of people globally and is the most common cardiac arrhythmia in clinical practice. The company's ablation and appendage management products are used by physicians during open-heart surgery and minimally invasive procedures, often in combination with catheter ablation performed by electrophysiologists.

Summarized from AtriCure, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.21
Return on equity-2.33%
Debt/equity0.12

Revenue, margins & earnings

FY2021 Net income: $50MFY2021 Taxes & interest: $5MFY2021 Operating expenses: $151MFY2021 Cost of revenue: $68M$274MFY2021FY2022: net loss $46M on revenue $330M$330MFY2022FY2023: net loss $30M on revenue $399M$399MFY2023FY2024: net loss $45M on revenue $465M$465MFY2024FY2025: net loss $11M on revenue $535M$535MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-24
  • 2026-09-24Chief Technical OfficerSale-4,519$271.1K
  • 2026-09-14DirectorSale-5,313$288.1K
  • 2026-09-10Chief Technical OfficerSale-3,657$201.1K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does AtriCure, Inc. do?

The company develops surgical products for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain.

When did ATRC last file with the SEC?

AtriCure, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-19. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:49 UTC. This page is also available as JSON at /api/data?ticker=ATRC and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ATRC and 5,000+ tickers.

Create a free account — keep ATRC
For your agent
GET /api/data?ticker=ATRC

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt